Quote:
Originally Posted by jfman
The time to develop a vaccine isn’t the issue - the mRNA companies say it can be days. Approval can be, to some degree, expedited. However mass production and distribution will remain a bottleneck.
The countries that are moving quickly with booster shots are just adding a third Pfizer shot, however Pfizer themselves are developing an updated vaccine for approval.
|
As I understand it, altering the formulation for a different genetic variant of the same virus does not then lead to the vaccine requiring the full re-trial and approval process, but simply an updated approval from the relevant authority. IN this sense approval is expedited by the vaccine’s very nature as a tweaked formula rather than a novel medicine.
But as you say, the bottleneck is production which is why we don’t already have delta-specific vaccines in use.